diethylcarbamazine has been researched along with Day Blindness in 5 studies
Diethylcarbamazine: An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eighteen patients, moderately to heavily infected with onchocerciasis, were treated with a standard course of diethylcarbamazine citrate (DEC-C)." | 7.66 | Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate. ( Anderson, J; Bird, AC; el-Sheikh, H; Fuglsang, H, 1980) |
| "Eighteen patients, moderately to heavily infected with onchocerciasis, were treated with a standard course of diethylcarbamazine citrate (DEC-C)." | 3.66 | Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate. ( Anderson, J; Bird, AC; el-Sheikh, H; Fuglsang, H, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ganesh, SK | 1 |
| Babu, K | 1 |
| Krishnakumar, S | 1 |
| Biswas, J | 1 |
| Taylor, HR | 1 |
| Greene, BM | 1 |
| Bird, AC | 2 |
| el-Sheikh, H | 2 |
| Anderson, J | 2 |
| Fuglsang, H | 2 |
| Tumada, LR | 1 |
| Margono, SS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study[NCT00511004] | Phase 2 | 40 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis[NCT04188301] | Phase 2 | 154 participants (Actual) | Interventional | 2019-12-06 | Completed | ||
| Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis[NCT06070116] | Phase 2 | 300 participants (Anticipated) | Interventional | 2024-01-15 | Not yet recruiting | ||
| Microfilarial Clearance From the Eye and Ocular Changes Associated With Ivermectin Treatment in Individuals With Onchocerciasis[NCT03517462] | 231 participants (Actual) | Interventional | 2018-08-06 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Doppler detected worm nests at 2 years (NCT00511004)
Timeframe: 2 years from the time enrolled.
| Intervention | Number of nests (Median) |
|---|---|
| Standard Therapy Annual DEC/ALB | 0 |
| High Dose Annual DEC/ALB | 0 |
| High Dose Semiannual DEC/ALB | 0 |
IgG4 antibodies directed against Brugia malayi antigen (NCT00511004)
Timeframe: 2 years
| Intervention | ng/ml (Median) |
|---|---|
| Standard Therapy Annual DEC/ALB | 150 |
| High Dose Annual DEC/ALB | 224 |
| High Dose Semiannual DEC/ALB | 128 |
Night time microfilarial counts at 1 year (NCT00511004)
Timeframe: 1 year from time enrolled
| Intervention | MF/ML (Median) |
|---|---|
| Standard Therapy Annual DEC/ALB | 0 |
| High Dose Annual DEC/ALB | 0 |
| High Dose Semiannual DEC/ALB | 0 |
Night time microfilarial levels at 2 years (NCT00511004)
Timeframe: 2 years from time enrolled
| Intervention | MF/ML (Median) |
|---|---|
| Diethylcarbamazine/Albendazole -STD | 0 |
| Diethylcarbamazine/Albendazole- HD1 | 0 |
| Diethylcarbamazine/Albendazole-HD2 | 0 |
The effectiveness of three treatment regimens for killing adult female O. volvulus worms based on the percentage of all adult female worms in nodules that are alive 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment
| Intervention | Female worms in nodule (Count of Units) |
|---|---|
| IVM + ALB | 127 |
| IDA x 1 Dose | 142 |
| IDA x 3 Doses | 159 |
The effect of three treatment regimens for killing adult female O. volvulus worms will be compared based on the percentage of all adult female worms in nodules that are alive with embryos in the uterus 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment.
| Intervention | Female worms in nodules (Count of Units) |
|---|---|
| IVM + ALB | 127 |
| IDA x 1 Dose | 142 |
| IDA x 3 Doses | 159 |
The effect of three treatment regimens for sterilizing adult female O. volvulus worms will be compared based on the percentage of all adult female worms that are fertile in the nodules 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment.
| Intervention | Female worms with intact uterus (Count of Units) |
|---|---|
| IVM + ALB | 41 |
| IDA x 1 Dose | 40 |
| IDA x 3 Doses | 34 |
Rates of ocular adverse events of any grade within 3 months will be compared by treatment group. (NCT04188301)
Timeframe: within 3 months of treatment with IDA
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 4 |
| IDA x 1 Dose | 4 |
| IDA x 3 Doses | 3 |
Rates of adverse events grade 3 or higher that occur within 7 days of treatment in the subset of participants who have intraocular microfilariae just prior to treatment with IDA will be compared by treatment group. (NCT04188301)
Timeframe: within 7 days following end of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 0 |
| IDA x 1 Dose | 0 |
| IDA x 3 Doses | 0 |
Rates of severe adverse events (grade 3 or higher) following 1-day or 3-day triple drug treatment will be compared against those of the comparator regimen of 1 day of IVM/ALB. (NCT04188301)
Timeframe: Within 7 days following end of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 0 |
| IDA x 1 Dose | 0 |
| IDA x 3 Doses | 0 |
The effectiveness of three treatment regimens for preventing reappearance of microfilariae in the skin as determined by skin snips at 12 and 18 months after treatment will be compared by treatment arm. Measured by the presence of microfilariae in skin snips. (NCT04188301)
Timeframe: Baseline, 12 months, and 18 months following treatment
| Intervention | Count of microfilarae+ participants (Number) | ||
|---|---|---|---|
| Baseline | Month 12 | Month 18 | |
| IDA x 1 Dose | 6 | 21 | 15 |
| IDA x 3 Doses | 0 | 21 | 17 |
| IVM + ALB | 7 | 23 | 20 |
The effectiveness of three treatment regimens for complete clearance of microfilariae from the skin as determined by skin snips at 3, 12, and 18 months after treatment with IDA will be compared by treatment arm. (NCT04188301)
Timeframe: Baseline, 3 months, 12 months, & 18 months following treatment.
| Intervention | Count of Skin Microfilaria (Geometric Mean) | |||
|---|---|---|---|---|
| Baseline | Month 3 | Month 12 | Month 18 | |
| IDA x 1 Dose | 1.7 | 3 | 2.5 | 9.0 |
| IDA x 3 Doses | NA | 2.1 | 4.7 | 8.6 |
| IVM + ALB | 3.1 | 1.9 | 4.9 | 7.0 |
1 trial available for diethylcarbamazine and Day Blindness
| Article | Year |
|---|---|
Ocular changes with oral and transepidermal diethylcarbamazine therapy of onchocerciasis.
Topics: Administration, Oral; Administration, Topical; Adult; Clinical Trials as Topic; Diethylcarbamazine; | 1981 |
4 other studies available for diethylcarbamazine and Day Blindness
| Article | Year |
|---|---|
Ocular filariasis due to Wuchereria bancrofti presenting as panuveitis: a case report.
Topics: Adult; Animals; Diethylcarbamazine; Eye Infections, Parasitic; Filariasis; Filaricides; Fundus Oculi | 2003 |
Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate.
Topics: Adolescent; Adult; Child; Diethylcarbamazine; Eye Diseases; Fluorescein Angiography; Humans; Male; M | 1980 |
Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate.
Topics: Adolescent; Adult; Child; Diethylcarbamazine; Eye Diseases; Fluorescein Angiography; Humans; Male; M | 1980 |
Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate.
Topics: Adolescent; Adult; Child; Diethylcarbamazine; Eye Diseases; Fluorescein Angiography; Humans; Male; M | 1980 |
Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate.
Topics: Adolescent; Adult; Child; Diethylcarbamazine; Eye Diseases; Fluorescein Angiography; Humans; Male; M | 1980 |
Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate.
Topics: Adolescent; Adult; Child; Diethylcarbamazine; Eye Diseases; Fluorescein Angiography; Humans; Male; M | 1980 |
Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate.
Topics: Adolescent; Adult; Child; Diethylcarbamazine; Eye Diseases; Fluorescein Angiography; Humans; Male; M | 1980 |
Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate.
Topics: Adolescent; Adult; Child; Diethylcarbamazine; Eye Diseases; Fluorescein Angiography; Humans; Male; M | 1980 |
Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate.
Topics: Adolescent; Adult; Child; Diethylcarbamazine; Eye Diseases; Fluorescein Angiography; Humans; Male; M | 1980 |
Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate.
Topics: Adolescent; Adult; Child; Diethylcarbamazine; Eye Diseases; Fluorescein Angiography; Humans; Male; M | 1980 |
Visual loss during oral diethylcarbamazine treatment for onchocerciasis.
Topics: Diethylcarbamazine; Humans; Male; Onchocerciasis; Sudan; Vision Disorders; Visual Acuity; Visual Fie | 1979 |
Cysticercosis in the area of the Wissel Lakes, West Irian.
Topics: Adolescent; Adult; Ascariasis; Cysticercosis; Diethylcarbamazine; Female; Headache; Hookworm Infecti | 1973 |